作者
Tomoyuki Nagao, Yasuya Inden, Masayuki Shimano, Masaya Fujita, Satoshi Yanagisawa, Hiroyuki Kato, Shinji Ishikawa, Aya Miyoshi, Satoshi Okumura, Shiou Ohguchi, Toshihiko Yamamoto, Naoki Yoshida, Makoto Hirai, Toyoaki Murohara
发表日期
2015/2
期刊
Pacing and Clinical Electrophysiology
卷号
38
期号
2
页码范围
155-163
简介
Introduction
Apixaban, a factor Xa (FXa) inhibitor, is a new oral anticoagulant for stroke prevention in atrial fibrillation (AF). However, little is known about its efficacy and safety as a periprocedural anticoagulant therapy for patients who had undergone catheter ablation (CA) for AF.
Methods and Results
We evaluated 342 consecutive patients who underwent CA for AF between April 2013 and March 2014 and received apixaban (n = 105) and warfarin (n = 237) for uninterrupted periprocedural anticoagulation. We retrospectively investigated the occurrence of bleeding and thromboembolic complications during the procedural period and compared them between the apixaban group (AG) and warfarin group (WG). Thromboembolic complications occurred in one (0.4%) patient in the WG. Major and minor bleeding complications occurred in one (1%) and four (4%) patients in the AG, and three (1%) and 12 (5 …
学术搜索中的文章
T Nagao, Y Inden, M Shimano, M Fujita, S Yanagisawa… - Pacing and Clinical Electrophysiology, 2015